The renal cancer pipeline presents key opportunities in developing novel therapies targeting immunosuppression and oncogenic pathways. Notable advancements include combinations like Quavonlimab with Pembrolizumab and small molecules such as Zanzalintinib, focusing on enhancing immune responses and overcoming resistance, showing promise in clinical trials. The renal cancer pipeline presents key opportunities in developing novel therapies targeting immunosuppression and oncogenic pathways. Notable